AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its Annual Report for 2018 is now available on the company’s website, www.alzecurepharma.se.
The information was submitted for publication, through the agency of the contact person set out below at 5.45pm CET on April 15, 2019.
For more information, please contact
Johan Sandin, CEO
Tel: +46 703 738 824
johan.sandin@alzecurepharma.com
About AlzeCure Pharma
AlzeCure Pharma AB is a Swedish pharmaceutical company listed on Nasdaq First North Premier, which engages in innovative pharmaceutical research with a primary focus on Alzheimer’s disease. The company is developing five drug candidates within its two research platforms NeuroRestore and Alzstatin. NeuroRestore consists of symptomatic drug candidates and Alzstatin consists of disease modifying drug candidates. Through a diversified drug portfolio which targets central signal mechanisms in the brain other indications such as cognitive disorders in traumatic brain injury, sleep apnea and Parkinson’s disease are also possible. FNCA Sweden AB is the company’s Certified Adviser, ph: +46 8-528 00 399, email: info@fnca.se. For more information, please visit www.alzecurepharma.se.
